NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1α protein in human ovarian cancer cells

Cancer Letters

Volumn 278, Issue 2, 2009, Pages 139-144

  Zhang, Ning ^a   Zhang, Hanwen ^a   Xia, Li ^b   Zheng, Ying ^b   Yu, Yun ^b   Zhu, Yuanshan ^c   Chen, Guoqiang ^b   Di, Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Camptothecin analog; Cisplatin; NSC606985; Ovarian neoplasms

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOCORTIN 5; NSC606985; PROTEIN KINASE C DELTA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; GROWTH DISORDER; HUMAN; HUMAN CELL; HYPOXIA; OVARY CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OVARIAN NEOPLASMS; PROTEIN KINASE C-DELTA;

EID: 64649089569     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.025     Document Type: Article

References (34)

1. Herzog T.J. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist 7 (2002) 3-10
2. Salzberg M.B., Thurlimann H., Bonnefois D., Fink C., Rochlitz R., Moos v., and Senn H. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 68 (2005) 293-298
3. Memarzadeh S., and Berek J.S. Advances in the management of epithelial ovarian cancer. J. Reprod. Med. 46 (2001) 621-629
4. Bookman M.A. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int. J. Gynecol. Cancer 15 (2005) 212-220
5. Pizzolato J.F., and Saltz L.B. The camptothecins. Lancet 361 (2003) 2235-2242
6. Ahmad T., and Gore M. Review of the use of topotecan in ovarian carcinoma. Expert. Opin. Pharmacother. 5 (2004) 2333-2340
7. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., and Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002) 4316-4324
8. Song M.G., Gao S.M., Du K.M., Xu M., Yu Y., Zhou Y.H., Wang Q., Chen Z., Zhu Y.S., and Chen G.Q. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms. Blood 105 (2005) 3714-3721
9. Liu W., Zhu Y.S., Guo M., Yu Y., and Chen G.Q. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic Leukemia. Leuk. Res. 31 (2007) 1565-1574
10. Tan C., Cai L.Q., Wu W., Qiao Y., Imperato-McGinley J., Chen G.Q., and Zhu Y.S. NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemother. Pharmacol. (2008)
11. Markman M. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist 12 (2007) 186-190
12. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
13. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 86 (1994) 1517-1524
14. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination Studies. Pharmacol. Rev. 58 (2006) 621-681
15. Yu Y., Wang L.S., Shen S.M., Xia L., Zhang L., Zhu Y.S., and Chen G.Q. Subcellular proteome analysis of camptothecin analog NSC606985-treated acute myeloid leukemic cells. J. Proteome. Res. 6 (2007) 3808-3818
16. Borst P., Rottenberg S., and Jonkers J. How do real tumors become resistant to cisplatin. Cell Cycle 7 (2008) 1353-1359
17. Huang Y., Du K.M., Xue Z.H., Yan H., Li D., Liu W., Chen Z., Zhao Q., Tong J.H., Zhu Y.S., and Chen G.Q. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia 17 (2003) 2065-2073
18. Bomgaars L., Berg S.L., and Blaney S.M. The development of camptothecin analogs in childhood cancers. Oncologist 6 (2001) 506-516
19. Basu A. Involvement of protein kinase C-delta in DNA damage-induced apoptosis. J. Cell Mol. Med. 7 (2003) 341-350
20. Kikuchi Y., Kita T., Takano M., Kudoh K., and Yamamoto K. Treatment options in the management of ovarian cancer. Expert. Opin. Pharmacother. 6 (2005) 743-754
21. Delaloge S., Laadem A., Taamma A., Chouaki N., Cvitkovic E., Pautier P., Misset J.L., and Lhomme C. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am. J. Clin. Oncol. 23 (2000) 569-574
22. Gordinier M.E., Kudelka A.P., Kavanagh J.J., Wharton J.T., and Freedman R.S. Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study. Int. J. Gynecol. Cancer 12 (2002) 710-714
23. Serova M., Calvo F., Lokiec F., Koeppel F., Poindessous V., Larsen A.K., Laar E.S., Waters S.J., Cvitkovic E., and Raymond E. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother. Pharmacol. 57 (2006) 491-499
24. Chou T.C. Preclinical versus clinical drug combination studies. Leuk. Lymphoma. 49 (2008) 2059-2080
25. Semenza G. L Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 407 (2007) cm 8
26. Nagy J.A., Masse E.M., Herzberg K.T., Meyers M.S., Yeo K.T., Yeo T.K., Sioussat T.M., and Dvorak H.F. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 55 (1995) 360-368
27. Kim K.S., Sengupta S., Berk M., Kwak Y.G., Escobar P.F., Belinson J., Mok S.C., and Xu Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 66 (2006) 7983-7990
28. Imai T., Horiuchi A., Wang C., Oka K., Ohira S., Nikaido T., and Konishi I. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163 (2003) 1437-1447
29. Spinella F., Rosano L., Di Castro V., Natali P.G., and Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J. Biol. Chem. 277 (2002) 27850-27855
30. Lee S., Garner E.I., Welch W.R., Berkowitz R.S., and Mok S.C. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol. Oncol. 106 (2007) 311-317
31. Shimogai R., Kigawa J., Itamochi H., Iba T., Kanamori Y., Oishi T., Shimada M., Sato S., Kawaguchi W., Sato S., and Terakawa N. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int. J. Gynecol. Cancer 18 (2008) 499-505
32. Birner P., Schindl M., Obermair A., Breitenecker G., and Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7 (2001) 1661-1668
33. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 12 (2007) 853-859
34. Beppu K., Nakamura K., Linehan W.M., Rapisarda A., and Thiele C.J. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. 65 (2005) 4775-4781